1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsEstablishes a clinical research network dedicated to designing and executing clinical studies to combat antimicrobial-resistant pathogens.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Higher education institutions, non-profit research organizations, and public entities. Confirm the full requirements in the official notice before applying.
Applications for Clinical Research Network on Antimicrobial Resistance are due November 10, 2026. Build your timeline backwards from this date to cover registrations, approvals, and final submission checks.
Clinical Research Network on Antimicrobial Resistance is funded by National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID). Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
Past winners and funding trends for this program
HIV/AIDS Clinical Trials Network Leadership and Operations Centers is sponsored by National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID). Supports Clinical Trials Networks Leadership and Operations Centers (LOC), Statistical and Data Management Centers, and Laboratory Centers working collaboratively to advance prevention, treatment, and implementation research designed to end the HIV epidemic.
Ending the HIV Epidemic: Clinical Trials Networks - Leadership and Operations Center (LOC) is sponsored by National Institutes of Health (NIH) / National Institute of Allergy and Infectious Diseases (NIAID). Supports clinical trials networks and community implementation research designed to advance HIV prevention, treatment, and support frameworks under the federal Ending the HIV Epidemic initiative.
The memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articleRFA-AI-28-005 recompetes NIAID's Immune Tolerance Network as a single UM1 cooperative agreement: $27M committed in FY2028, budgets capped at $23M a year in direct costs, a mandatory 7-year project period, one application per institution, and a January 29, 2027 deadline. The winner inherits roughly 20 ongoing trials and about 200 sub-agreements.
Read articleNIAID's RFA-AI-28-024 funds preclinical malaria vaccines, from AI-guided design to cGMP lots, through a phased R61/R33. It allows one application per institution, bars foreign subawards, and excludes GLP tox.
Read article